- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07728630
Endothelial Extracellular Vesicles as Biomarkers of Endothelial Activation in Adults With Newly Diagnosed Hypertension (HYPER-endoEV-a)
22. juli 2026 opdateret af: Ines Drenjancevic, Josip Juraj Strossmayer University of Osijek
Endothelial Extracellular Vesicles as Biomarkers of Blood Pressure-Induced Endothelial Activation in Adults With Newly Diagnosed Untreated Hypertension
Hypertension is associated with endothelial dysfunction, an early event in the development of cardiovascular disease.
Endothelial extracellular vesicles (EEVs) have emerged as promising biomarkers of endothelial activation and vascular injury; however, their relationship with blood pressure and microvascular endothelial function in untreated hypertension remains insufficiently understood.
This observational case-control study aims to compare circulating EEV concentrations between normotensive adults and adults with newly diagnosed, untreated primary hypertension.
In addition, the study will investigate the associations between EEV levels, blood pressure, microvascular endothelial function assessed by laser Doppler flowmetry, and established circulating biomarkers of endothelial activation.
The findings may improve understanding of the role of EEVs in early hypertension and support their potential use as non-invasive biomarkers of endothelial dysfunction and cardiovascular risk.
Studieoversigt
Status
Rekruttering
Betingelser
Undersøgelsestype
Observationel
Tilmelding (Anslået)
80
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Ivana Jukić, MD, PhD
- E-mail: ivana.jukic@mefos.hr
Undersøgelse Kontakt Backup
- Navn: Ana Stupin, MD, PhD
- Telefonnummer: +38531512800
- E-mail: ana.stupin@mefos.hr
Studiesteder
-
-
-
Osijek, Kroatien, 31000
- Rekruttering
- Faculty of Medicine Osijek
-
Kontakt:
- Ana Stupin, MD, PhD
- Telefonnummer: +38531512800
- E-mail: ana.stupin@mefos.hr
-
Kontakt:
- Ivana Jukić, MD, PhD
- Telefonnummer: +38531512800
- E-mail: ivana.jukic@mefos.hr
-
Ledende efterforsker:
- Ivana Tolj, MD, PhD
-
Underforsker:
- Marko Stupin, MD, PhD
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ja
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
The study population will consist of adult men and women aged 18 years and older recruited from the outpatient clinics of the University Hospital Centre Osijek, Croatia.
The study will include normotensive individuals and patients with newly diagnosed, previously untreated primary hypertension.
Healthy volunteers will serve as the control group.
Beskrivelse
Inclusion Criteria:
- Adults aged 18 years or older.
- Ability and willingness to provide written informed consent.
- Normotensive individuals or individuals with newly diagnosed, previously untreated primary hypertension, classified according to the European Society of Hypertension (ESH) guidelines.
- Ability to comply with all study procedures.
Exclusion Criteria:
- Secondary hypertension.
- Previous treatment with antihypertensive medication.
- History of cardiovascular disease (except newly diagnosed primary hypertension in the hypertensive group).
- Diabetes mellitus.
- Chronic kidney disease.
- Cerebrovascular disease.
- Peripheral arterial disease.
- Acute or chronic inflammatory or infectious disease.
- Active malignancy.
- Pregnancy or breastfeeding.
- Current use of oral contraceptives, hormone replacement therapy, or medications known to affect endothelial function.
- Inability or unwillingness to provide informed consent.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Normotensive Controls
Adults aged 18 years or older with normal office blood pressure according to the European Society of Hypertension (ESH) guidelines and without a history of hypertension or antihypertensive treatment.
|
|
Adults With Newly Diagnosed Untreated Primary Hypertension
Adults aged 18 years or older with newly diagnosed, previously untreated primary hypertension according to the European Society of Hypertension (ESH) guidelines and no prior use of antihypertensive medication.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma endothelial extracellular vesicle concentration
Tidsramme: Baseline
|
Concentration of circulating endothelial extracellular vesicles quantified by flow cytometry following size-exclusion chromatography isolation.
|
Baseline
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Acetylcholine-induced vasodilation (AChID)
Tidsramme: Baseline
|
Endothelium-dependent microvascular vasodilation assessed by acetylcholine iontophoresis and laser Doppler flowmetry.
|
Baseline
|
|
Sodium nitroprusside-induced vasodilation (SNPID)
Tidsramme: Baseline
|
Endothelium-independent microvascular vasodilation assessed by sodium nitroprusside iontophoresis and laser Doppler flowmetry.
|
Baseline
|
|
VCAM-1 concentration
Tidsramme: Baseline
|
Plasma vascular cell adhesion molecule-1 (VCAM-1) concentration measured as a marker of endothelial activation.
|
Baseline
|
|
ICAM-1 concentration
Tidsramme: Baseline
|
Plasma intercellular adhesion molecule-1 (ICAM-1) concentration measured as a marker of endothelial activation.
|
Baseline
|
|
Endocan concentration
Tidsramme: Baseline
|
Plasma endocan concentration measured as a marker of endothelial dysfunction.
|
Baseline
|
|
Matrix metalloproteinase-9 (MMP-9)
Tidsramme: Baseline
|
Plasma MMP-9 concentration measured as a marker of vascular remodeling and endothelial dysfunction.
|
Baseline
|
|
PORH response (R-O%)
Tidsramme: Baseline
|
Microvascular endothelium-dependent vasodilation assessed by laser Doppler flowmetry following 1-minute arterial occlusion.
|
Baseline
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Efterforskere
- Studiestol: Ana Stupin, MD, PhD, Faculty of Medicine Osijek, Josip Juraj Strossmayer of Osijek
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. maj 2026
Primær færdiggørelse (Anslået)
30. april 2029
Studieafslutning (Anslået)
30. september 2029
Datoer for studieregistrering
Først indsendt
22. juli 2026
Først indsendt, der opfyldte QC-kriterier
22. juli 2026
Først opslået (Faktiske)
27. juli 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
27. juli 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
22. juli 2026
Sidst verificeret
1. maj 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HYPER-endoEV-adults
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .